To evaluate the efficacy and remission at week 54 of Vedolizumab in inflammatory bowel disease (IBD) in a multicenter cohort of patients.

Trial Profile

To evaluate the efficacy and remission at week 54 of Vedolizumab in inflammatory bowel disease (IBD) in a multicenter cohort of patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Apr 2017 New trial record
    • 29 Mar 2017 Results published in the Digestive Diseases and Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top